Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06034002 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
A Phase 1 study of Myeloproliferative Neoplasms, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 230
- Enrollment target
- 13
- Study locations
NCT06034002: Recruiting Phase 1 study of Myeloproliferative Neoplasms, sponsored by Incyte Corporation.
NCT06034002 is a Phase 1 study of Myeloproliferative Neoplasms that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 230 participants, above the 123-participant average among 8 other Myeloproliferative Neoplasms trials with a reported enrollment target (87% higher). The trial reports 13 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06034002, a Phase 1 study of Myeloproliferative Neoplasms, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 230 participants
- Enrollment target
- 13
- Study locations
Study Summary
This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a Monotherapy or in Combination With Ruxolitinib in participants with myeloproliferative neoplasms.
Primary Outcome
Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol.
Conditions Studied
Interventions
- DRUG Ruxolitinib
- DRUG INCA033989
Study Locations (13)
California
- City of Hope Medical Center - Duarte
- Stanford Cancer Institute - Palo Alto
New York
- Icahn School of Medicine At Mount Sinai - New York
- Memorial Sloan Kettering Cancer Center - New York
Florida
- University of Miami Health System - Miami
Kansas
- The University of Kansas Cancer Center - Westwood
Maryland
- Johns Hopkins Hospital - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Missouri
- Washington University School of Medicine - St Louis
North Carolina
- Wake Forest Baptist Medical Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2023-12-04 |
| Est. Completion | 2028-10-29 |
| Phase | Phase 1 |
What NCT06034002 shows while recruiting
NCT06034002 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, above the 123-participant average among 8 other Myeloproliferative Neoplasms trials with a reported enrollment target (87% higher).
The record links to 1 condition, with Myeloproliferative Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Ruxolitinib is the first listed.
NCT06034002 lists 13 locations in 11 states (California, New York, Florida).
Frequently Asked Questions
What is clinical trial NCT06034002 about?
NCT06034002 is a clinical study titled "A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms". This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a Monotherapy or in Combination With Ruxolitinib in participants with myeloprol...
What is the current status of trial NCT06034002?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 230 participants. The study started on 2023-12-04. Estimated completion is 2028-10-29.
What conditions does trial NCT06034002 study?
This clinical trial studies the following conditions: Myeloproliferative Neoplasms.
What interventions are being tested in trial NCT06034002?
The interventions under investigation include: Ruxolitinib (DRUG), INCA033989 (DRUG).
Who is sponsoring clinical trial NCT06034002?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06034002 being conducted?
This trial has 13 study locations across California, Florida, Kansas, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloproliferative Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06034002's enrollment target sits among peer trials
230 2nd of 8 the highest of 8 other Myeloproliferative Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myeloproliferative Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
RECRUITING · Phase 1
-
Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
RECRUITING · Phase 1
-
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
RECRUITING · Phase 1
-
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
ACTIVE NOT RECRUITING · Phase 1
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI